Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B2 | P19099 | 17/20 | 0.65 |
| ▸ | NOTUM | Q6P988 | 2/20 | 0.35 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.32 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.32 |
| ▸ | IKZF3 | Q9UKT9 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17456315 | 1.00 | CYP11B2 (0.65) | CYP11B2NOTUMDDB1CRBNIKZF3 | |
| SCHEMBL21832029 | 0.79 | CYP11B2 (1.00) | CYP11B2 | |
| SCHEMBL17456291 | 0.77 | CYP11B2 (0.67) | CYP11B2 | |
| SCHEMBL31307574 | 0.77 | CYP11B2 (0.67) | CYP11B2 | |
| SCHEMBL21832014 | 0.72 | CYP11B2 (1.00) | CYP11B2 | |
| SCHEMBL17456273 | 0.70 | CYP11B2 (0.61) | CYP11B2 | |
| SCHEMBL30480912 | 0.70 | CYP11B2 (0.61) | CYP11B2 | |
| SCHEMBL22751722 | 0.70 | CYP11B2 (1.00) | CYP11B2 | |
| SCHEMBL17456297 | 0.68 | CYP11B2 (0.53) | CYP11B2 | |
| SCHEMBL14403997 | 0.66 | DRD2 (0.52) | CYP11B2DDB1CRBNIKZF3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12263157-B2 | Aldosterone synthase inhibitors for treating chronic kidney disease | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2025-04-01 | — | — | US | disclosed |
| US-20250049763-A1 | ALDOSTERONE SYNTHASE INHIBITORS FOR TREATING CHRONIC KIDNEY DISEASE | BOEHRINGER INGELHEIM INT (DE) | 2025-02-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250049763-A1 | ALDOSTERONE SYNTHASE INHIBITORS FOR TREATING CHRONIC KIDNEY DISEASE | SLC5A2, SLC5A1, REN | CYP11B2 10/4885NOTUM 2157/4885DDB1 4610/4885 |
| US-12263157-B2 | Aldosterone synthase inhibitors for treating chronic kidney disease | SLC5A1, SLC5A2, REN | CYP11B2 12/4885NOTUM 2293/4885DDB1 4481/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.